Due to the current crisis of COVID-19 pandemic in Thailand, the in-person conference is not allowed. The APBMT 2021 Organizing Committee has to organize the 26th Congress of Asia Pacific Blood and Marrow Transplantation (APBMT 2021) as a Virtual event.

Message from President

Dear friends and colleagues,
I hope this message will find you all well. I believe that we are all working very hard to get us through this difficult time during the last couple of years. Though the pandemic is very challenging, we have witnessed how great human endeavor against this pandemic can be. Many scientific achievements have been accomplished within record breaking time. And I believe that stem cell transplantation and cell therapy will benefit from these progresses as well.

It is an honor for The Thai Society of Hematology to be the host of Asia Pacific Blood and Marrow Transplantation (APBMT) Congress this year. The Congress will be held in Chiang Mai, Thailand on October 15-17, 2021. We will carry on the tradition of APBMT in promoting collaborative works in this region and around the world, together with bringing state of the arts education topics to the audience. The collaboration and experience sharing are at their best if we can meet on site. However, we are planning for this Conference as a hybrid meeting if the situation does not permit or international travelling cannot resume to normalcy.

I would like to cordially invite you to join us in the 26th APBMT Congress. Chiang Mai is a very beautiful and pleasant city. It has been a major tourist destination for several decades due to its charming culture and environment. It would be a great honor for us to welcome you there.
Sincerely,

Artit Ungkanont, M.D.
President, APBMT 2021

Meeting Room 1
Time Title
8.30-09.00
GVHD prophylaxis and biomarkers

•    Introduction
Auro Viswabadya
Princess Margaret Cancer Centre, Canada
Udomsak Bunworasate
Chulalongkorn Hospital/University, Thailand

09.00-09.50
GVHD Prophylaxis and Biomakers

•    Novel approach in GVHD prophylaxis
     Takanori Teshima  (Japan)

09.50-10.00
GVHD Prophylaxis and Biomakers

Q&A

10.00-10.30
Refreshment | Exhibition
10.30-10.35
Stem cell transplantation in non-malignant diseases

Introduction
David Ma
St Vincent's Hospital Sydney, Australia
Kleebsabai Sanpakit
Mahidol university, Thailand

10.35-12.00
Stem Cell Transplantation in Non-Malignant Disease

Q&A

12.00-13.00
Luncheon Symposium I: Novartis

“Advances in the biology & management of GVHD”
Moderator: Surapol Issaragrisil (Thailand)
•    Advances in acute GVHD
     Yok-Lam Kwong (Hong Kong)
•    Advances in chronic GVHD
     Sung-Soo Yoon (South Korea)

13.00-14.00
Luncheon Symposium II: Takeda

Moderator: Udomsak Bunworasate (Thailand)

•    Interactive case-based panel discussion on managing CMV in the high-risk HCT transplant recipient
     Per Ljungman (Sweden)

14.00-14.30
Pediatric transplantation

•     แนะนำวิทยากร
      Amir Hamidieh
      Tehran University of Medical Sciences , Iran
      Piya Rujkjyanont
      Department of Pediatrics, Phramongkutklao Hospital, Thailand
•    Allogeneic HSCT for pediatric solid tumors 
     Rupert Handgretinger (Germany)

14.30-14.55
Pediatric Transplantation

•    HSCT in congenital immune deficiencies
     Pamela Lee (Hong Kong)

14.55-15.30
Pediatric Transplantation

Q&A

15.30-16.00
Refreshment | Exhibition
16.00-17.30
Novel treatments in GVHD

•    Introduction
     Gan Gin Gin
     Dept. of Medicine, U. of Malaya, Malaysia
     Kitsada Wudhikarn
     Department of Medicine, Chulalongkorn University, Thailand
•    Update on treatment of chronic GVHD
     Yoshihiro Inamoto (Japan)

16.30-16.55
Novel treatments in GVHD

•    Novel drugs for GVHD
     Robert Zeiser (Germany)

16.55-17.30
Novel treatments in GVHD

Q&A

17.30-18.45
Dinner Symposium: Gilead – Kite Pharma

“Reaching new landmarks in survival with CAR T-cell therapy in haematological malignancies”
Chairperson: Ana Sureda (Spain)

•    CAR T in lymphoma: What do the data tell us?
             - Jim Kochenderfer (USA)
             - Frederick Locke (USA)
             - Ana Sureda (Spain)
             - Irit Avivi (Israel)
             - Robin Sanderson (UK)
             - Caron Jacobson (USA)
             - Mohamad Mohty (France)
             - Weili Zhao (China)

Meeting Room 2
Time Title
08.30-08.35
CAR T cell toxicities and management

•   Chair 
      Tong Wu
      Beijing Boren Hospital, China
      Usanarat Anurathapan
      Mahidol University, Thailand

08.35-09.00
CAR T Cell Toxicities and Management

•    Biology of CAR T toxicities
      Shui Yen Soh (Singapore)

09.00-09.25
CAR T Cell Toxicities and Management

•    Infectious complications, immune constitution and prophylactic strategies after CAR T cell therapy
      Kitsada Wudhikarn (Thailand)

09.25-10.00
CAR T Cell Toxicities and Management

Q and A

10.00-10.30
Refreshment | Exhibition
10.30-10.35
Present and future of cell and gene therapy

•    Chair
      Yoshiki Akatsuka
      Nagoya University Graduate School of Medicine, Japan
      Suradej Hongeng
      Mahidol University, Thailand

10.35-11.00
Present and future of cell and gene therapy

•    How to make accessible and affordable CAR T cell with GMP facility?
      Usanarat Anurathapan (Thailand)

11.00-11.25
Present and future of cell and gene therapy

•    Non-viral based CAR T cell manufacturing
      Yoshiyuki Takahashi (Japan)

11.25-12.00
Present and future of cell and gene therapy

Q and A

12.30-14.00
APBMT Business Meeting
14.00-15.30
Oral presentation 1

Chairpersons: Phu Chi Dung (Vietnam), Kannadit Prayongratana (Thailand)

O-1-1
The outcome of hematopoietic stem cells transplantation (HSCT) in pediatric patients in COVID-19  pandemic: Impact of Delta Variate

            Leila Jafari (Iran)
O-1-2
Higher CD34+ cell dose and rapid natural killer cell recovery improve clinical outcome after transplantation in patients with myeloid malignancies

            Fei Zhao (China)
O-1-3
The study of microRNAs in CD34+ HSPCs from AML patients with relapse after allogeneic transplantation

           Fei Zhao (China)
O-1-4
Pre-transplant immune suppression prevents graft rejection in children with IFN-gamma receptor defect mendelian susceptibility to mycobacterial disease

          Rumesh Chandar (India)
O-1-5
The outcome of peripheral blood HSCT with myeloablative conditioning regimen in MIOP patients

          Rashin Mohseni (Iran)
O-1-6
Tacrolimus offers an effective GVHD prophylaxis with a tolerable toxicity profile in pediatric hematopoietic stem cell transplantation

          Rumesh Chandar (India)

15.30-16.00
Refreshment | Exhibition
16.00-17.30
Oral presentation 2

Chairperson: Carmella Lou Bingcang (Philippines), Adisak Tantiworawit (Thailand)

O-2-1
Safety, feasibility and healthcare cost differences between inpatient and outpatient mobilization chemotherapy for autologous hematopoietic stem cell transplantation in multiple myeloma: A single center experience

          Edwin Wei Sheng Thong (Singapore)
O-2-2
Evaluating cost saving and value driven outcomes in implementing outpatient peripheral blood stem cell (PBSC) collection: A nurse-led quality improvement initiative

          Hui Li Lim (Singapore)
O-2-3
Eltrombopag improves platelet recovery after allogeneic hematopoietic stem cell transplantation

           Yahan Li (China)
O-2-4
The efficacy of ice flakes with syrup for cryotherapy to prevent chemotherapy-induced oral mucositis in patients undergoing autologous stem cell transplantation

          Supannee Sainumyen (Thailand)
O-2-5
Outcomes of antiemetic protocol in patients undergoing hematopoietic stem cell transplantation based on real-world practice

          Jarukamol Khanthawong (Thailand)
O-2-6
Autologous stem cell transplantation in an hiv-positive patient with multiple myeloma during the COVID-19 pandemic

          Joseph Emmanuelle Siatan (Philipines)

COMMITTEES

APBMT Executive Board

Chair Shinichiro Okamoto (Japan)
Vice-Chair Alok Srivastava (India)
Members David D. Ma (Australia)
He Huang (China)
Amir Ali Hamidieh (Iran)
Jong Wook Lee (Korea)
William YK Hwang (Singapore)

APBMT 2021 Organizing Committee

Chair Shinichiro Okamoto (Japan)
Vice-Chair Alok Srivastava (India)
Advisors Saengsuree Jootar
Surapol Issaragrisil
Tanin Intragumtornchai
Ponlapat Rojnuckarin
President Artit Ungkanont
Chair of Scientific Program Suradej Hongeng
Co-Chair of Scientific Program Udomsak Bunworasate
Secretary-General 1 Adisak Tantiworawit
Secretary-General 2 Usanarat Anurathapan
Members Ekapun Karoopongse
Kanhatai Chiengthong
Kannadit Prayongratana
Kitsada Wudhikarn
Kleebsabai Sanpakit
Oytip Na Thalang
Pimjai Niparuck
Piya Rujkityanont
Vandee Ningsanond

Speakers

Usanarat Anurathapan

Ramathibodi Hospital, Mahidol University Bangkok, Thailand

Division of Hematology and Oncology Department of Pediatrics

Japp J. Boelens

Transplantation and Cellular Therapy Center Department of Pediatrics Memorial Sloan Kettering Cancer Center New York, NY, USA

Nelson Chao

Division of Hematologic Malignancies and Cellular Therapy Department of Medicine, Duke University School of Medicine Durham, North Carolina, USA

Godfrey Chi-Fung Chan

Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital & HKU-Shenzhen Hospital, The University of Hong Kong, Hong Kong

Sharat Damodar

The Bone Marrow Transplant Unit Narayana Health City Mazumdar Shaw Medical Center Bangalore, Karnataka, India

Stella Davies

Division of Bone Marrow Transplantation and Immune Defficiency Cincinnati Children’s Hospital Medical Center Cincinnati, Ohio, USA

Juan Du

The Second Military Medical University Shanghai, P.R. China

Department of Hematology The Myeloma & Lymphoma Center Shanghai Changzheng Hospital

David Gottlieb

Westmead Clinical School The Westmead Institute for Medical Research – BMT University of Sydney, Australia

Hildegard Greinix

Waehringer Guertel, Vienna, Austria

Department of Medicine I Bone Marrow Transplantation Unit University of Vienna

Amir Ali Hamidieh

Tehran University of Medical Sciences Tehran, Iran

Pediatric Stem Cell Transplant Department Children’s Medical Center

Rupert Handgretinger

Department of Hematology/Oncology Children’s University Hospital Tubingen Germany

Suradej Hongeng

Ramathibodi Hospital, Mahidol University Bangkok, Thailand

Division of Hematology and Oncology Department of Pediatrics

William Hwang

National Cancer Centre Singapore

Yoshihiro Inamoto

Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo, Japan

Natee Jearawiriyapaisarn

Thalassemia Research Center Institute of Molecular Biosciences Mahidol University, Nakhon Pathom 73170, Thailand

Nutcharee Jungvanichar

Chief Nursing Officer Bumrungrad International Hospital Bangkok, Thailand

Hiroshi Kawamoto

Laboratory of Immunology Institute for Frontier Life and Medical Sciences (IFLMS) Kyoto University, Japan

Bor Sheng Ko

Department of Internal Medicine National Taiwan University Hospital (China, Taiwan)

Nicolaus Kröger

Department of Stem Cell Transplantation University Hospital Hamburg – Eppendorf Hamburg, Germany

Philippe Leboulch

Department of Medicine Brigham and Women’s Hospital 75 Francis St., Boston, MA 02115, USA

Pamela Lee

Department of Paediatrics & Adolescent Medicine Queen Mary Hospital, The University of Hong Kong Hong Kong

John E. Levine

The Mount Sinai School of Medicine Director of BMT Clinical Research New York, USA

Francesca Lorraine Lim

Department of Haematology Singapore General Hospital Singapore

David Ma

St.Vincent’s Clinical School University of New South Wales, Australia

Lt.Gen.Velu Nair

Internal Medicine, Clinical Hematology & Bone Marrow Transplant Armed Forces Medical Service, India

Shinichro Okamoto

Division of Hematology Department of Medicine Keio University of Medicine Tokyo, Japan

Vivek Roy

Division of Hematology/Oncology Department of Internal Medicine Mayo Clinic Jacksonville Jacksonville, Florida, 32224 USA

Matthew Porteus

Institute of Stem Cell Biology & Regenerative Medicine Department of Pediatrics, Division of Hematology/Oncology and Human Gene Therapy Stanford School of Medicine USA

Ho Ying Shi

Block 7 Level 2 Haematology Pharmacy Singapore General Hospital Singapore

John A. Snowden

Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, Sheffield, UK

Shui Yen Soh

Paediatric Haematology/Oncology Service KK Women's and Children's Hospital (KKH), Singapore.

Alok Srivastava

Department of Haematology Christian Medical College, Vellore, India

Takanori Teshima

Department of Hematology Director, Hematology and BMT program Hokkaido University, Japan

Dr.Trai Tharnpanich

Department of Pharmacy Practice, Chulalongkorn University, 254, Phayathai Road, Pathumwan, Bangkok 10330 Thailand

Naoyuki Uchida

Department of Hematology Toranomon Hospital Tokyo 105‐0001, Japan.

Daniel Weisdorf

Division of Hematology, Oncology and Transplantation University of Minnesota, Minneapolis, USA

Kitsada Wudhikarn

Division of Hematology Department of Medicine King Chulalongkorn Memorial Hospital Chulalongkorn University, Bangkok, Thailand

Lim Yan Yin

Nurse Manager the Children’s Cancer Centre KK Women’s and Children’s Hospital Singapore

Bo Yu

Deputy Chief Pharmacist Department of Pharmacy, Shanghai Tongren Hospital 1111 Xian-Xia Road, Shanghai 200032; P.R. China

Robert Zeiser

Hematology and Oncology University Medical Center Freiburg Freiburg, Germany